A landmark Phase 2 study will test smoked, high-THC flower versus placebo in 320 veteran participants with moderate to severe PTSD. Here’s what’s being studied and why it matters for DMV patients.

A power shift at Lykos Therapeutics could revive MDMA-assisted therapy—and Rick Doblin’s influence. Here’s what’s changing, why it matters, and how DMV residents should watch the next moves.

Most psychedelic use happens outside hospitals. Here’s why community-led, non-clinical models matter—and how DMV patients can navigate access, safety, and support today.

A new federal push to speed psychedelic therapies highlights ibogaine and VA trials, but funding cuts, workforce gaps, and ethics could slow real-world access.

A tense exchange at Psychedelic Culture put ethics of research in conflict zones under a microscope—raising questions for psychedelic science, patient access, and the DMV.

A one-month show at the Berkeley Alembic opens the Shulgin archive—letters, lab gear, rave ephemera—and offers timely lessons for the DMV’s cannabis culture.

A new nonprofit, After The Story, will fund legal psychedelic-assisted care and integration for reporters and media workers carrying trauma from the job.

MAPS linked with New Jersey’s HoneyProjects to bring education into a dispensary setting—its first retail cannabis partnership in 40 years—and it could reshape how patients learn.

From Bicycle Day to modern art prints, here’s how LSD blotter design latched onto space themes—and why the revival matters for DC, Maryland, and Virginia culture.

At Chacruna’s Psychedelic Culture Conference, protesters challenged MAPS over work in Israel, igniting a raw debate on ethics, equity, and community accountability.

Resilient Pharmaceuticals submits a renewed application for MDMA-assisted PTSD therapy, seeking FDA approval without a fresh Phase 3 trial.

From NFL safety to wellness frontman, Jordan Poyer’s Breath of Life tour blends breathwork, sound, and ceremony. Here’s why the DMV is paying attention.